PARP1 and early-onset autosomal dominant Alzheimer disease: Based on these results, we suggest that drugs targeting PARP1, mitochondrial respiration, and ATP synthase may hold potential as chemotherapeutic agents when combined with DNA damage-inducing drugs in cardiovascular diseases, Alzheimer’s disease, and cancer.